Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

R99

—

eba06302-1e55-54b8-80cc-a24d95bdb88b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.680
  • ANGIOGENESIS+0.570
  • WNT_BETA_CATENIN_SIGNALING+0.410
  • HEDGEHOG_SIGNALING+0.400
  • COAGULATION+0.370
  • MYOGENESIS+0.350
  • NOTCH_SIGNALING+0.350
  • PANCREAS_BETA_CELLS+0.340
  • APICAL_JUNCTION+0.320
  • MYC_TARGETS_V2+0.240

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.570
  • PROTEIN_SECRETION-0.470
  • INTERFERON_GAMMA_RESPONSE-0.370
  • PI3K_AKT_MTOR_SIGNALING-0.360
  • PEROXISOME-0.270
  • ANDROGEN_RESPONSE-0.240
  • FATTY_ACID_METABOLISM-0.190
  • BILE_ACID_METABOLISM-0.150
  • HEME_METABOLISM-0.150
  • MITOTIC_SPINDLE-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-AC-A7VC-01A-11R-A352-07
breast-umap@18
—A0.820
2R297
bladder-landscape@3
——0.816
3SRR23303757
bladder-landscape@3
——0.800
4SRR5088843
melanoma-umap@29
——0.792
5TCGA-LL-A5YP-01A-21R-A28M-07
breast-umap@18
—E0.776
6MNG762
mng-umap@100
——0.770
7TCGA-CN-6989-01A-11R-1915-07
head-neck@1
——0.769
8SRR8613770
breast-umap@18
—E0.748
9C3L-02619
lung-landscapes@6
—cohortSQ10.740
1040b92a76-f324-4cdd-8209-517d021acd47
melanoma-umap@29
——0.738

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.680Inavolisib— uncovered
ANGIOGENESIS0.570Remibrutinib— uncovered
WNT_BETA_CATENIN_SIGNALING0.410Inavolisib— uncovered
HEDGEHOG_SIGNALING0.400Inavolisib— uncovered
COAGULATION0.370Binimetinib— uncovered
MYOGENESIS0.350Inavolisib— uncovered
NOTCH_SIGNALING0.350Inavolisib— uncovered
PANCREAS_BETA_CELLS0.340Cobimetinib— uncovered
APICAL_JUNCTION0.320Inavolisib— uncovered
MYC_TARGETS_V20.240Idelalisib— uncovered
APICAL_SURFACE0.230Temsirolimus— uncovered
KRAS_SIGNALING_UP0.230Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.180Idelalisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.160Remibrutinib— uncovered
SPERMATOGENESIS0.150Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.140Inavolisib— uncovered
IL2_STAT5_SIGNALING0.130Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.130Inavolisib— uncovered
HYPOXIA0.120Idelalisib— uncovered
ALLOGRAFT_REJECTION0.090Idelalisib— uncovered